Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Primerdesign launches Exsig Mag RapidBead Pro Extraction kit

December 2025—Primerdesign launched its Exsig Mag RapidBead Pro Extraction kit, a next-generation magnetic bead–based kit used to extract high-quality DNA and RNA from diverse sample types. The workflow reduces hands-on time compared to traditional methods and extracts DNA and RNA in less than 20 minutes.

Bruker gets expanded clearance for MALDI Biotyper CA system

December 2025—Bruker announced that its MALDI Biotyper CA system received expanded clearance from the FDA. The clearance includes the MBT Compass HT CA software and MBT Fast Shuttle US IVD as well as an expansion of the FDA-cleared reference library.

Clear Labs collaborates with Labcorp, Pillar Biosciences

December 2025—Clear Labs announced at the Association for Molecular Pathology annual meeting (Boston, Nov. 11–15) its collaboration with Labcorp to automate PGDx kitted oncology NGS assays on the Clear Dx platform. Clear Labs says the collaboration aims to develop streamlined, end-to-end workflows that help laboratories improve efficiency, consistency, and throughput while laying the groundwork for future adoption across a range of genomic applications. This new workflow will expand Clear Labs’ infectious disease applications into oncology testing.

IDT, Beckman Coulter partner to automate NGS workflows

December 2025—Integrated DNA Technologies and Beckman Coulter Life Sciences are forming a strategic partnership to automate IDT’s customizable next-generation-sequencing assay solutions on Beckman Coulter’s newly launched Biomek i3 benchtop liquid handler. Through this partnership, the companies will work to automate IDT’s Archer FusionPlex and VariantPlex targeted sequencing assays and xGen Hybrid Capture workflows on the Biomek i3 system.

HemoSonics gets expanded clearance for Quantra system

December 2025—HemoSonics has received FDA 510(k) clearance for expanded use of its Quantra hemostasis system with QStat cartridges in peripartum obstetric procedures. It is the first FDA-cleared viscoelastic testing platform for obstetric bleeding, according to a company press release. The system uses SEER (sonic estimation of elasticity via resonance) sonorheometry to measure the coagulation properties of a whole blood sample. It provides results in about 15 minutes.

FDA clears Simplexa COVID-19, flu A/B, RSV Direct kit

December 2025—Diasorin has received FDA 510(k) clearance for the Simplexa COVID-19/Flu A/B and RSV Direct kit, a sample-to-answer test for the detection of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus directly from nasopharyngeal and nasal swab specimens. The kit runs on the Liaison MDX system and provides differential detection in about 45 minutes.

ARUP study validates AI for parasite detection

December 2025—The Journal of Clinical Microbiology has published an article describing ARUP Laboratories’ validation of a deep convolutional neural network to detect parasites in concentrated wet mounts of stool.

Smart In Media releases v3.2 of PathoZoom-SL

December 2025—Smart In Media has released version 3.2 of its PathoZoom Scan and LiveView. The new version includes enhancements to workflow, image transmission, and LIS integration.

Qiagen to acquire Parse Biosciences

December 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research, for $225 million. The acquisition will expand Qiagen’s Sample technologies portfolio into the single-cell sequencing market with highly scalable chemistry designed to power research involving millions of billions of cells, according to a press release from Qiagen. Parse’s scalable chemistry is also expected to accelerate growth in Qiagen’s digital insights bioinformatics business.

FDA approves Ortho Vision, MTS DAT card

December 2025—The FDA has approved QuidelOrtho Corp.’s Micro Typing Systems DAT card, a gel-based solution for direct antiglobulin testing, and the Ortho Vision platform, an automated blood testing system.